Press Releases
Pharmacy
Brokerage
Valuation
Consultancy

Record-breaking year with a third of pharmacies in 2024 sold to new market entrants, reveals Christie & Co annual report

Specialist business property adviser, Christie & Co, has today launched its Business Outlook 2025 report which reflects on the themes, activity and challenges of 2024 and forecasts what 2025 might bring across the sectors in which Christie & Co operates, including in the pharmacy sector.

Business. Built around You.

Your expert business property advisers

Jonathan Board

Jonathan Board

Head of Pharmacy

Business Outlook 2025 cover image for press

Market overview

The calling of a swift General Election in July 2024 caught many by surprise and, frustratingly for the sector, this sidelined any potential announcement of a new funding deal as this fell foul of the pre-election sensitivity period. Following Labour’s landslide election victory, the Party appointed Stephen Kinnock as its new Pharmacy Minister, along with a host of other appointments across healthcare. Also of note, Pharmacists Sadik Al-Hassan and Taiwo Owatemi now sit as parliamentary MPs, which, one would hope, will provide better insight into the sector’s challenges and drive the necessary changes from the inside.

Whilst any funding announcement was delayed in 2024, it is hoped that more positive news will be received in early 2025. A minor boost was also received by the sector with the introduction of the Pharmacy First service in England, which has already been operating successfully in both Scotland and Wales (CAS) for a couple of years now. The implementation wasn’t without its challenges, however, with some minor adjustments to activity thresholds in October last year, it is hoped that the delivery of the service will continue to improve to the benefit of patients and importantly provide much-needed additional income to contractors.

Transactional activity

​Throughout 2024, transactional activity was buoyant despite ongoing operational challenges. In the 12 months to end of November 2024, Christie & Co completed 222 pharmacy sales, more than double the amount for the preceding year. 36 per cent of these were corporate disposals which the broker expects to subside in 2025 and be replaced with an increasing volume of independent sales.

First-time buyers were the most active buyer type in 2024, acquiring 33 per cent of pharmacy businesses on the market with Christie & Co, this is down from 45 per cent in 2023. In contrast, large groups and corporate operators made up just 8 per cent of acquisitions last year.

Pricing

Christie & Co notes an average decrease of 6.3 per cent in the price per pharmacy businesses sold last year. While 2024 was a record year for transactional activity, with deal volume at an all-time high despite ongoing operational challenges and cost pressures, the distressed pharmacies that came to the market all generated significant interest from buyers keen to acquire competitively priced opportunities on both a local and a regional basis. This negative price movement, therefore, was a product of the high numbers of smaller pharmacies and corporate disposals sold in the first half of the year. Encouragingly, the last quarter saw a vast increase in the average value of the pharmacies being added to our pipelines (offers made and deals being accepted), which will no doubt positively impact our price index in 2025.

An average of 91 per cent of asking price was achieved on pharmacy businesses in 2024, which is a decrease on the year before which saw offers accepted at an average of 2.5 per cent above asking price.

Market sentiment

As part of its annual sentiment survey, Christie & Co asked pharmacy professionals across the country for their views on the year ahead. When questioned about their sentiment in 2025, 22 per cent said they feel positive while the majority (50 per cent) feel negative, which can be attributed to the uncertainty around funding in the sector. When asked about their sale and acquisition plans, 68 per cent stated that they are looking to buy and/or sell this year.

Predictions

In the pharmacy market in 2025, Christie & Co expects:

  • Cost challenges will remain a key factor in the market, none more so than the increase in National Living Wage (NLW) from April 2025
  • It is hoped that, with an improved funding settlement, levels of distress in the sector will subside
  • A continuation of the improvement seen in Q4 2024 of the volume of independent sales as corporate disposal processes start to subside
  • Improved appetite from group operators to acquire as some cost pressures stabilise
  • Private equity is expected to renew its focus on the sector, as it is one of the few primary care sectors not to have seen significant investor appetite

Jonathan Board, Head of Pharmacy at Christie & Co, comments, “2024 was a record year from pharmacy transactions due in part to an increased level of corporate divestments. As we move into 2025, the entire sector is waiting with bated breath for an announcement on the outcome of pharmacy’s wider funding agreement which will replace the Community Pharmacy Contractual Framework’s 5-year deal from 2019. This will hopefully provide some certainty for all contractors moving forwards and allow them to plan and invest accordingly. Although cost pressures will continue to be a feature for the foreseeable future, market appetite remains strong for well-established, well-run businesses as well as the numbers of pharmacies sold over the last 12 months, but as highlighted in the Christie & Co Pharmacy Market Review 2024, it’s likely that market appetite in England will be tempered by the outcome of the much-needed funding settlement negotiations.”

To read the full business outlook report, visit: https://www.christie.com/news-resources/business-outlook-2025/pharmacy/

---------------------

For further information on this press release, contact:
Phoebe Hill, Associate Director – Corporate Communications
P: 07540 063 598 or E: phoebe.hill@christie.com

Related Articles

View other related news and insights